BioGeneration III Services BV

Foundation date

10/11/2006

Sector

#Investor

Subsector

BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech companies. The Company has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €250 million ($300 million) of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together.

 BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.

Upcoming events

Latest news

  • Biotalys Appoints Laura J. Meyer to Board of Directors

    Tuesday April 30th 2024

  • V-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitors

    Wednesday April 24th 2024

  • Labconsort and NEKTARI join forces for a more sustainable and social industry

    Saturday April 20th 2024